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The pathophysiology of intestinal
lipoprotein production
Antonina Giammanco, Angelo B. Cefalù, Davide Noto and Maurizio R. Averna*
Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy
Intestinal lipoprotein production is a multistep process, essential for the absorption of
dietary fats and fat-soluble vitamins. Chylomicron assembly begins in the endoplasmic
reticulum with the formation of primordial, phospholipids-rich particles that are then
transported to the Golgi for secretion. Several classes of transporters play a role in the
selective uptake and/or export of lipids through the villus enterocytes. Once secreted in
the lymph stream, triglyceride-rich lipoproteins (TRLs) are metabolized by Lipoprotein
lipase (LPL), which catalyzes the hydrolysis of triacylglycerols of very low density
lipoproteins (VLDLs) and chylomicrons, thereby delivering free fatty acids to various
tissues. Genetic mutations in the genes codifying for these proteins are responsible of
different inherited disorders affecting chylomicron metabolism. This review focuses on
the molecular pathways that modulate the uptake and the transport of lipoproteins of
intestinal origin and it will highlight recent findings on TRLs assembly.
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Introduction
Dietary fats are taken up by enterocytes of the small intestine and packaged into chylomicrons.
Chylomicrons (CMs) are triglyceride-rich lipoproteins (TRLs) with a central lipid core and a layer
of phospholipids (6–12%), free cholesterol (1–3%), and apolipoproteins (1–2%) and play an essen-
tial role in the transport of triglycerides and fat-soluble vitamins (Hamilton, 1972). Hepatocytes,
in turn, secrete TRLs as very low density lipoprotein (VLDL)particles (Hamilton, 1972). Both CMs
and VLDLs are hydrolyzed mainly by lipoprotein lipase (LPL) in the circulation and processed
into CM remnants and low density lipoprotein (LDL) respectively. In this review we will focus on
the physiological mechanisms, pathways and genes that modulate the uptake and the transport of
lipoproteins of intestinal origin. We will first discuss the synthesis and maturation steps of the pri-
mordial lipoprotein particles of intestinal origin and the processes of secretion in the circulation.
Afterward, we will briefly focus on the extra-intestinal fate of CMs and we will give an overview
on the inherited disorders affecting CMs metabolism. Finally we will highlight recent findings on
TRLs assembly.
Intestinal Lipid Absorption: an Overview
Growing bodies of evidences indicate, both in humans and animal models, that the small
intestine is not only involved in the absorption of dietary lipids but actively regulates the
production and secretion of CMs (Abumrad et al., 1993; Cartwright et al., 2000; Mansbach
and Gorelick, 2007; Khosrow and Lewis, 2008). The process of dietary lipid absorption is
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traditionally divided into three components: (a) uptake into the
enterocyte, (b) intracellular processing, and (c) transport into
the circulation (Mansbach and Gorelick, 2007; Khosrow and
Lewis, 2008; Abumrad and Davidson, 2012). Pancreatic lipase
makes the first step possible through the hydrolysis of dietary
fats, mostly triacylglycerols (TAG), within the lumen of the small
intestine. Fatty acids (FA) and sn-2-monoacylglycerol (MAG) are
the results of this enzymatic breakdown (Mansbach andGorelick,
2007). Hydrolysis products are then transported across the apical
brush border membrane of the enterocyte by cluster determinant
36 (CD 36) (Abumrad and Davidson, 2012). The FA are then
bound by FA binding proteins (FABPs) and targeted to microso-
mal compartments for re-esterification to triglycerides (Khosrow
and Lewis, 2008). De-novo lipogenesis represents another valid
source of triglycerides useful for lipidation and this process is
hormone-dependent (Khosrow and Lewis, 2008).
CM assembly is a complex process that needs the activity
of microsomal triglyceride transfer protein (MTP) to cotransla-
tionally incorporate apoB-48 into a phospholipids-rich, dense,
primordial chylomicron particle (prechylomicron) (Kumar and
Mansbach, 1999; Hussain, 2000; Levy et al., 2002). Then, prechy-
lomicrons are included in a unique transport vesicle, the prechy-
lomicron transport vesicle (PCTV), which is budded off the
endoplasmic reticulum (ER) membrane and transported to the
Golgi (Kumar and Mansbach, 1999; Hussain, 2000). Once into
the Golgi compartment several chylomicrons fuse into another
transport vesicle and are transported to the basolateral mem-
brane for secretion in the circulation (Hussain, 2000; Jones et al.,
2003).
Two different models have been proposed for CMs assembly
(Cartwright et al., 2000; Hussain, 2000). According to Hussain,
the assembly of small nascent lipid poor CM particles and buoy-
ant triglyceride-rich chylomicrons progress through independent
pathways (Hussain, 2000).
On the other hand the so called “core expansion” model, pro-
poses that primordial chylomicrons and triglyceride-rich lipid
droplets of various sizes join together to form lipoproteins of
different size (Cartwright et al., 2000).
In the next sections we will focus on recent advancing in
understanding the process of intestinal assembly and trafficking
of CMs.
Major Pathways and Genes Involved in
Chylomicrons Metabolism
Small intestine enterocytes absorb cholesterol and FA both
through passive diffusion and protein-facilitated FA transfer
(Abumrad and Davidson, 2012). Over the years, several classes
of long chain fatty acids (LCFA) transporters have been shown to
be involved in the selective uptake and/or export of dietary lipids
to the sub-apical domain of the villus enterocyte (Abumrad and
Davidson, 2012). CD 36, originally identified as a receptor for
oxidized low-density lipoproteins (Endemann et al., 1993), is a
75–88 kDa, 472 aminoacid glycosilated transmembrane protein,
which actually show a wide ligand specificity for LCFA, different
lipoproteins, glycosylated proteins, thrombospondin-1 and other
molecules (Silverstein and Febbraio, 2009). CD 36 is ubiquitously
expressed and major sites of synthesis are heart, skeletal muscle,
adipose tissue, intestine (Abumrad et al., 1993), and the capillary
endothelium (Greenwalt et al., 1995). Several in vitro and in vivo
studies have demonstrated that CD 36 facilitates the LCFA tissue
uptake (Coburn et al., 2000; Hajri et al., 2002) and it plays a rele-
vant role in the pathogenesis of metabolic disorders and athero-
genesis (Abumrad et al., 1993;Watanabe et al., 1998; Hirano et al.,
2003; Ma et al., 2004; Yamashita et al., 2007; Love-Gregory et al.,
2011).
The uptake of FA both in the intestine and liver is also
mediated by fatty acid binding proteins (FABPs). FABPs are
small cytosolic proteins (14 kDa) belonging to a multigene fam-
ily expressed both in the intestine (Intestinal-FABP, IFABP or
FABP2) and in the liver (liver-FABP, LFABP or FABP1) (Abum-
rad et al., 1993). IFABP is able to bind one FA molecule while
LFABP binds two FA molecules in addition to a wide range of
other lipids (Hamilton, 2004; Storch and Thumser, 2010).
Intestinal triglyceride-rich lipoprotein assembly needs two
major players, both of which must be available simultaneously
for this process to proceed to completion: (a) apolipoprotein B
(apoB), which is the acceptor for the neutral lipid donor and
(b) microsomal triglyceride transfer protein (MTP) (Chen and
Davidson, 2012). ApoB is an essential structural component of
the surface of lipoprotein particles. TRLs cannot be assembled
without apoB being present. In humans, TRLs are assembled
in liver and intestine in a tissue-specific manner. In the liver
full-length apoB (apoB-100) is assembled into VLDL (Davidson
and Shelness, 2000). In human enterocytes, a post-transcriptional
editing of the apoB mRNA transcript gives rise exclusively to a
truncated form of apoB (apoB-48) (Davidson and Shelness, 2000)
for the assembly of CMs (Hussain, 2000). CMs are larger particles
than hepatic VLDLs and beside apoB they also contain multiple
copies of smaller apolipoproteins including apoA-I, apoA-IV and
apoC-III. These apolipoproteins are important for VLDL and/or
chylomicrons assembly but not essential as apoB (Hussain, 2000;
Hussain et al., 2005).
The nascent ApoB is translocated across the ER membrane
where MTP interacts with the apoB N-terminal domain (Liang
et al., 2000). This interaction promotes the transfer of lipids
from the ER membrane to the nascent apoB leading to the for-
mation of a primordial lipoprotein particle (Liang et al., 2000).
When lipid availability is limited or MTP function impaired, the
nascent apoB becomes misfolded and undergoes ubiquitination
and degradation through the proteasomal pathway (Liang et al.,
2000). This step may occur either outside the ER or within the
ER lumen (Fisher et al., 2001). MTP also directs the assembly of
apoB-free triglyceride-rich particles within the adjacent smooth
ER (SER) (Mansbach and Gorelick, 2007). During intracellu-
lar lipoprotein assembly, the nascent lipoprotein particle joins
with SER TG-rich lipid droplets, resulting in prechylomicron
formation (Mansbach and Gorelick, 2007). Once this process is
completed prechylomicrons are enriched of vesicular transport
proteins, including coatomer proteins II (COPII) to be incor-
porated into a vesicular complex through ER membrane bud-
ding ready to fuse with Golgi membranes apparatus (Jones et al.,
2003; Mansbach and Gorelick, 2007). Vesicles containing nascent
Frontiers in Physiology | www.frontiersin.org 2 March 2015 | Volume 6 | Article 61
Giammanco et al. The pathophysiology of intestinal lipoprotein production
CMs are then secreted into the pericellular spaces adjacent to
lymphatic fenestrae (Mansbach and Gorelick, 2007). The COPII
machinery has been shown to have a critical role in transporting
TRL particles from the ER to the Golgi (Barlowe et al., 1994; Iko-
nen, 2008). Among the protein components of COPII machinery,
Sar1b, a member of the Sar1/Arf family of small GTPase, is an
essential player in the last step of assembly of this vesicular trans-
port complex (Shoulders et al., 2004). Chylomicron-retention
disease (CMRD) due to mutations in the SAR1B gene, encoding
for Sar1b, is an example of failure in the transport of prechy-
lomicrons through the secretory pathway even though the ER
assembly process takes place correctly (Cefalù et al., 2010; Shoul-
ders et al., 2014). Therefore, prechylomicrons accumulate in the
membrane-bound compartments of enterocytes. Notably muta-
tions of the SAR1B gene that are associated with CMRD do not
impair VLDL packaging and secretion (Jones et al., 2003; Shoul-
ders et al., 2004). This observation warrants further evaluations
to better understand the mechanisms regulating intestinal lipid
assembly and secretion.
Biogenesis of Chylomicrons: a Multistep
Process
Chylomicron Formation within the ER Lumen
CMs are synthesized through a multistep process that begins in
the endoplasmatic reticulum (Figure 1). In the first step a high-
density particle consisting of apoB-48, phospholipids, apoA-IV,
cholesterol, and small amounts of TAG is formed to give rise
nascent chylomicron particles. Then, these particles join with a
large apoB-free TAG-cholesterol ester mass to form a prechy-
lomicron particle, which is transferred to the cis-Golgi (Yam-
aguchi et al., 2006; Mansbach and Gorelick, 2007). In the rough
endoplasmic reticulum (RER), newly synthesized apoB-48 inter-
acts with the luminal MTP. ApoB-48 then may follow two des-
tinies: (a) it may form tight complexes with lipid rich particles
containing mostly phospholipids, cholesterol and small amounts
of triacylglycerol or (b) it may be rapidly degraded if associa-
tion with lipids does not occur. In the SER, triacylglycerol and
cholesterol esters are transported by MTP from their site of syn-
thesis on the ER membrane to an enlarging particle stabilized by
a phospholipid-cholesterol monolayer and merged with apoA-IV
to form a large light particle (LP). This particle buds from the
SER surrounded by a membrane. It has been reported that this
step is mediated by L-FABP, but not COPII proteins and it also
requires ATP (Yamaguchi et al., 2006; Mansbach and Gorelick,
2007). If TAG-rich particles lack apoB-48 are unable to leave the
ER suggesting that the apoB-48 on the surface of the TAG-rich
particle indicates that the prechylomicron is ready to be exported
(Ojakian et al., 2006; Mansbach and Gorelick, 2007).
Export of Pre-Chylomicrons from the ER
After the pre-chylomicrons are synthesized, these intracellu-
lar particles leave the ER and are vehicled through the secre-
tory pathway for further modification (Abumrad and Davidson,
2012).
Once prechylomicrons are formed in the ER they need to
translocate to and fuse with the Golgi complex. There are some
FIGURE 1 | Biogenesis of chylomicrons. The formation of chylomicrons
occurs in a two-step process within the ER lumen. In the first step, newly
synthesized apolipoprotein B48 (in blue) is chaperoned by the luminal protein,
microsomal triglyceride transfer protein (MTP, in purple) into the rough
endoplasmic reticulum (RER). The apoB then follows two destinies: it can form
stable complexes with dense particles (DP, in orange) containing mostly
phospholipids, cholesterol and small amounts of triacylglycerol (above) or is
rapidly degraded in the absence of association with lipids (below). In the
smooth endoplasmic reticulum (SER), the triacylglycerol and cholesterol esters
(in yellow) are carried from their site of synthesis on the ER membrane to an
enlarging particle through MTP and is incorporated to apolipoprotein A-IV
(apoA-IV, in green) to form a large particle, which buds from the SER
surrounded by a membrane, resulting in prechylomicron transport vesicle
(PCTV) formation. Other proteins, including L-FABP (in red) and CD 36 (in
black), also participate in PCTV formation. After fusion with key vesicular
transport proteins, such COPII (in violet), the prechylomicrons are incorporated
into a vesicular complex that translocate to and fuse with the Golgi complex.
Here, apoA-I arrives in different transport vesicles than PCTV and attaches to
the chylomicrons to form a mature chylomicron containing apoA-I, apo A-IV
and apo B48 (not shown). The mature chylomicrons exit the Golgi complex in
large transport vesicles that fuse with the basolateral membrane and are
secreted.
important distinctions between the chylomicron transport sys-
tem and the transport of other newly synthesized proteins. In fact
the very large size of prechylomicrons requires a specific trans-
porter; PCTVs are large enough to carry prechylomicrons and
are able to fuse with the cis-Golgi (Mansbach and Gorelick, 2007).
Furthermore, PCTVs are unique compared to other protein
vesicles because they enclose the v-soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (v-SNARE) and the
vesicle associated membrane protein 7 (VAMP-7) (Siddiqi et al.,
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2003, 2010a; Mansbach and Gorelick, 2007). Several studies
suggest that the COPII proteins are able to select protein cargo
to be included into the vesicle, deform the ER membrane and
break up the budding vesicle from the ER membrane to form the
nascent protein transport vesicle. These events take place at spe-
cific ER exit sites marked by secretory proteins (Sec16 and Sec23)
(Mansbach and Gorelick, 2007). These transport vesicles protect
their cargo from cytosolic proteases by providing a closed space
and contain on their surface information that enables them to be
targeted to the cis-Golgi (Mansbach and Gorelick, 2007).
The COPII machinery plays a unique role in vesicular bud-
ding and trafficking of ER cargo destined for secretion through
the Golgi apparatus (Mansbach and Siddiqi, 2010). Studies in rat
enterocytes demonstrated that the sequential interaction of het-
erodimeric COPII proteins (Sec 23/24 and Sec 13/31) is required
for prechylomicrons budding from the ER to the Golgi appara-
tus (Siddiqi et al., 2010a,b). Data from animal model (adult rat)
have suggested that budding of the PCTV is the rate-limiting
step in lipid absorption (Siddiqi et al., 2006). Neeli et al. (2007)
have recently indicated that L-FABP can select cargo and bud the
PCTV from the ERmembrane. Studies on intestinal extracts sug-
gest that ER budding and formation of the PTCVs do not require
COPII proteins while trafficking and fusion with the cis-Golgi is
dependent on COPII proteins Sar1b and Sec23/24 (Siddiqi et al.,
2010a) as well as a soluble N-ethylmaleimide-sensitive factor
attachment protein receptor (SNARE), fusion complex composed
of vesicle-associated membrane protein 7 (VAMP7), synthaxin
5, Bet1, and vti1a (Black, 2007). PCTV budding is impaired in
intestinal extracts prepared from CD36−/− mice, suggesting a
role for this multifunctional receptor (Siddiqi et al., 2003). More-
over, studies in L-Fabp−/− and in CD 36−/− mice have also
shown that the kinetics of intestinal TG secretion is significantly
slower suggesting an important functional regulation of PCTV
formation arbitrated by L-FABP and CD 36 (Drover et al., 2005,
2008; Newberry et al., 2006). On the other hand, studies in a rat
hepatoma cell model demonstrated that a functional COPII com-
plex is required for ER budding of the nascent apoB100-VLDL
particle (Gusarova et al., 2003). Studies on intestinal PCTV have
been suggested a potential mechanism of the CM-independent
secretion of apoprotein A-I (ApoA-I), another apolipoprotein
involved in CM assembly (Mansbach and Gorelick, 2007). Indeed
ApoA-I secretion is not combined with the CM secretion (Mans-
bach and Gorelick, 2007) probably because PCTV are lacking
of apoA-I (Siddiqi et al., 2003) and the transport vesicle that
exports apoA-I from the ER to the Golgi is different and likely
to be the COPII-dependent protein transport vesicle. Therefore,
at the Golgi, apoA-I arrives in different transport vesicles than the
PCTV (Siddiqi et al., 2003). Once into the Golgi apparatus, apoA-
I binds to the prechylomicron to form a mature chylomicron
containing apoA-I, apoA-IV and apoB-48 (Mansbach and Gore-
lick, 2007). The mature chylomicrons leave the Golgi complex in
large transport vesicles that join with the basolateral membrane
and are finally secreted (Mansbach and Siddiqi, 2010).
Chylomicron Secretion
CMs output into the circulation correlates with the amount of
dietary phosphatidylcholine (PC) in the intestinal lumen, the
amount of fat in the diet, the expression of apoA-IV by the ente-
rocytes and the hydratation state of the mucosa (Voshol et al.,
2000).
High fat diet increases the transport of biliary PC and apoA-
IV plays a role in the induction of the CM-TAG secretion mainly
by increasing the size of the CMs (Lu et al., 2006; Black, 2007).
In addition the ability to export CMs into the blood stream
depends of the hydration state of the intestine.
ApoA-IV is a lipid-binding protein that is synthesized by ente-
rocytes in response to lipid absorption (Green et al., 1980; Apfel-
baum et al., 1987; Elshourbagy et al., 1987) and it is secreted in
association with primordial chylomicrons into mesenteric lymph
(Kalogeris et al., 1996; Kumar and Mansbach, 1999); once CMs
are secreted and undergo lipolysis, a significant fraction of the
apoA-IV dissociates because of the narrowing of CMs surface and
then is transferred to HDL and lipoprotein-free fractions (Tso
et al., 1984; Ohta et al., 1985; Hayashi et al., 1990). Intestinal lipid
absorption, as well as CM secretion, regulates ApoA-IV expres-
sion (Zannis et al., 1980; Weinberg et al., 1990; Kalogeris et al.,
1997). Therefore, the presence of apoA-IV in the peripheral cir-
culation is dependent on the intestinal formation and secretion of
lipid. ApoA-IV also cooperates in several physiological functions
as an antioxidant (Kalogeris et al., 1998), anti-inflammatory fac-
tor (Vowinkel et al., 2004), anti-atherosclerotic factor (Duverger
et al., 1996; Cohen et al., 1997), a mediator of reverse-cholesterol
transport (Dvorin et al., 1986; Stein et al., 1986), and acute satiety
factor (Fujimoto et al., 1992; Tso et al., 2001). All of these impor-
tant functions of apoA-IV may be redundant roles since other
apolipoproteins are involved in such processes (Green et al., 1980;
Apfelbaum et al., 1987; Elshourbagy et al., 1987).
ApoA-IV neither acts to stabilize the CM-TAG, nor it
is necessary for the packaging of TAG into CMs but it is
mainly involved in secretion and further metabolism in the
circulation (Kohan et al., 2012, 2013; Wang et al., 2012).
Moreover the lack of apoA-IV delays the clearance of CMs
(Kohan et al., 2012).
Recently it has been shown that apoA-IV plays an impor-
tant role in mediating glucose homeostasis by stimulating insulin
secretion and that the loss of apoA-IV significantly impairs
glucose homeostasis and peripheral lipid clearance. ApoA-
IV KO mice display defective insulin release from pancre-
atic islets and impaired glucose tolerance compared to wild
type (WT) mice, particularly on high fat diet (HFD) (Wang
et al., 2012). Administration of exogenous apoA-IV in apoA-IV
KO mice improves glucose tolerance improving insulin secre-
tion rates (Wang et al., 2012). A recent report has shown
that in patients undergoing gastric bypass surgery plasma lev-
els of apoA-IV increases after surgery and correlates with an
improved glucose tolerance (Culnan et al., 2009). ApoA-IV
appears to be an endogenous regulator of insulin secretion with
tight interactions with other components of the enteroinsular
axis.
ApoA-IV is post-translationally regulated by the glucagon-
like peptide-1 (GLP-1), a gut incretin that modulates insulin
secretion in response to carbohydrates and FA intake (Drucker,
2001; Hein et al., 2013). GLP-1 acts by stimulating insulin secre-
tion and decreasing the availability of apo B-48 and TG for
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assembly and secretion of CMs (Hsieh et al., 2010). Moreover
the administration of exogenous recombinant GLP-1 (rGLP-1)
in diabetic rats inhibits apoA-IV secretion and TG absorption
(Drucker, 2001; Qin et al., 2005).
Recent evidences have also emphasized the crucial role of
another intestinal peptide, the glucagon-like peptide-2 (GLP-2),
in the intestinal lipid homeostasis (Estall and Drucker, 2006;
Hsieh et al., 2008; Hein et al., 2013; Dash et al., 2014). GLP-2 is
secreted together with GLP-1, but it exerts opposite effect on CMs
assembly and secretion and specifically it enhances the secre-
tion of CMs from enterocytes. (Estall and Drucker, 2006; Meier
et al., 2006; Hsieh et al., 2010; Dash et al., 2014). When GLP-
1 and GLP-2 are co-infused intravenously in normal subjects
for a short time (30min) lipid absorption is increased suggest-
ing a predominat GLP-2 action (Hein et al., 2013). However,
under prolonged (120min) co-infusion, the action of GLP-1
prevails by decreasing post-prandial CMs assembly and secre-
tion (Hein et al., 2013). It’s notheworthy that GLP-1 is rapidly
degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) (Hein
et al., 2013). All together these findings suggest that promot-
ing GLP-1 activity, either by agonist-based therapies or DPP-4
inhibitors, may be helpful to manage dyslipidemia in insulin-
resistant/diabetic conditions (Hsieh et al., 2010; Xiao et al., 2012,
2014; Hein et al., 2013; Matikainen and Taskinen, 2013). On
the other hand, antagonizing GLP-2 may be a good strategy to
decrease the post-prandial secretion of CMs (Dash et al., 2014).
All together these data warrant further investigations on the role
of apoA-IV, GLP-1, and GLP-2 as modulators of lipid and glucose
homeostasis.
Extra-Intestinal Mechanisms of
Triglyceride-Rich Lipoproteins Metabolism
Once chylomicrons are secreted and transported via the intesti-
nal lymphatic system they enter the blood stream where they
are metabolized by Lipoprotein lipase (LPL), which plays a key
role in the hydrolysis of triacylglycerols of VLDLs and CMs. LPL
is synthesized in parenchymal cells of various organs, including
adipose and skeletal muscle, and it is secreted and transported
to the luminal surface of vascular endothelium where hydrolysis
occurs. Active LPL is a homodimer that is bound to heparan sul-
fate chains on the surface of endothelial cells (Cheng et al., 1981;
Cupp et al., 1987). LPL requires apolipoprotein C-II (APOC-II)
as a cofactor for efficient lipolysis of TRLs in the circulation
(Wilson, 1990). The lack of ApoC-II or defects in its structure
severely impair LPL-mediated lipolysis and consequently TGs
accumulate in plasma (Di Filippo et al., 2014). Recently, three
new proteins have been identified as essential players for proper
LPL function: apoA-V, lipase maturation factor 1 (LMF1) and
glycosylphosphatidylinositol-anchored HDL binding protein 1
(GPIHBP1). The primary known function of apoA-V is to act as
cofactor and stimulate LPL and plasma clearance of TRLs (Gon-
zales et al., 2013) LMF1 has been shown to be essential for the
maturation of both LPL and hepatic lipase (HL) to their full func-
tional forms (Peterfy et al., 2007). GPIHBP1 has been identified as
the endothelial protein that facilitates LPL trafficking toward the
endothelial cell surface and provides a platform for TG lipolysis
(Beigneux et al., 2007; Davies et al., 2010).
Inherited Disorders Affecting Chylomicron
Metabolism
As previously discussed MTP is an intracellular lipid-transfer
protein essential for the assembly and secretion of VLDL parti-
cles and CMs by initiating the incorporation of lipids into ApoB
and by acting as a chaperone to assist in the proper folding of the
Apo B protein (Kane, 1989; Wetterau et al., 1997). The role of
MTP in lipid transport and metabolism was revealed by studies
demonstrating that a genetic defect in MTP gene causes abetal-
ipoproteinemia, a condition characterized by lack of production
of ApoB containing lipoproteins (CMs and VLDL).
Abetalipoproteinemia (ABL; OMIM 200100) is a rare auto-
somal recessive disease due to mutations in both alleles of the
MTP gene; affected patients exhibit nearly undetectable levels of
ApoB and very low plasma cholesterol levels. Due to the impair-
ment of lipoprotein assembly, patients develop fatmalabsorption,
steatorrhea and fat accumulation in enterocytes and hepatocytes
(Kane, 1989; Wetterau et al., 1997). The steatorrhea is usually
minimized as subjects learn to avoid fat rich diets at an early age.
Subjects also suffer from multiple vitamin deficiencies (E, A, K,
and D) because these fat soluble vitamins require the intestinal
TRLs for normal absorption and transport. If untreated, affected
subjects will develop various neurological disturbances includ-
ing spinal-cerebellar degeneration, peripheral neuropathies and
retinitis pigmentosa. These conditions can be prevented by sup-
plementation of fat soluble vitamin early in life (Haghpassand
et al., 1996; Wetterau et al., 1997; Hussain et al., 2012).
The role of molecular inactivating defects of MTP as cause
of ABL suggested that inhibition of MTP could be a novel
pharmacological target to lower plasma lipid levels.
Recently a phase 3 trial with lomitapide, a pharmacologi-
cal inhibitor of MTP has been successfully used as adjunctive
treatment in homozygous familial hypercholesterolemia (HoFH)
patients (Cuchel et al., 2013; Golberg, 2013).
Homozygous hypobetalipoproteinemia (Ho-HBL; OMIM
107730) is another extremely rare inherited disorder character-
ized by improper packaging and secretion of apoB-containing
lipoproteins due to mutations in both alleles of the APOB gene
(Schonfeld, 2003; Tarugi and Averna, 2011). Themajority of them
are either carriers of homozygous or compound heterozygous
mutations in APOB gene leading to apoB truncations or amino
acid substitutions (Lee and Hegele, 2014; Cefalù et al., 2015). The
clinical manifestations of patients with molecularly defined Ho-
FHBL are variable ranging from lack of symptoms to the pres-
ence of clinical features overlapping with those of ABL (Lee and
Hegele, 2014; Cefalù et al., 2015).
When truncated apoBs species are smaller than apoB-48, the
apoB form produced by the intestine and incorporated into chy-
lomicrons, these short abnormal apoBs lose the capacity to bind
lipids and form chylomicrons that are secreted from the entero-
cytes into the intestinal lymph (Tarugi and Averna, 2011; Lee and
Hegele, 2014; Cefalù et al., 2015).
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Chylomicron retention disease (CMRD) or Anderson’s Dis-
ease (OMIM #607689) is a rare, autosomic recessive disorder
usually diagnosed in infants presenting with chronic diarrhea,
failure to thrive, hypocholesterolemia and low fat-soluble vitamin
levels (Anderson et al., 1961; Lee and Hegele, 2014; Cefalù et al.,
2015). The specific molecular defect was identified in 2003 and
consists of mutations in the SAR1B gene which encodes for intra-
cellular Sar1b protein (Strich et al., 1993; Shoulders et al., 2004;
Hussain et al., 2005; Cefalù et al., 2010). This protein is involved
in the transport of chylomicron through the secretory pathway
(see Section Chylomicron Secretion). The enterocytes of jeju-
nal mucosa of these patients fail to secrete CMs in the lymph
and are consequently overloaded with lipid droplets heteroge-
neous in size and distribution (Strich et al., 1993). The mucosal
surface of the small intestine, as observed by endoscopy, is cov-
ered with a whitish layer (“a white stippling-like hoar frosting”
or gele’e blanche). Bloating of the abdomen, osteomalacia, and
rickets have been observed in several cases. Fatty liver has been
described without any evolution to more severe forms of hepatic
disease (Charcosset et al., 2008). CMRD is clinically distinguish-
able from ABL and Ho-HBL by the absence of acanthocytosis,
retinitis pigmentosa, and severe neurological symptoms and the
detection of circulating apoB-100-containing lipoproteins.
HTG is a hallmark of both Fredrickson type 1 and type 5
hyperlipidemias. Type 5 hyperlipidemia encompasses a mixed
hyperlipidemic phenotype including elevated levels of both
CM and VLDL remnants particles (Xiong et al., 1991; Brun-
zell and Fujimoto, 1995; Berriot-Varoqueaux, 2004). The clini-
cal syndrome, referred to as Type I hyperlipoproteinemia, also
known as familial chylomicronemia, is characterized by mas-
sive hypertriglyceridemia, abdominal pain, pancreatitis, eruptive
xanthomas and hepatosplenomegaly occurring at a frequency of
about one in a million in general population (Xiong et al., 1991;
Brunzell and Fujimoto, 1995; Berriot-Varoqueaux, 2004).
LPL and APOC-II gene mutations (Breckenridge et al., 1978;
Auwerx et al., 1989; Brunzell and Austin, 1989) together with
mutations occurring in the APOA-V, LMF1 and GPIHBP1 are
responsible for monogenic forms of familial chylomicronemia
(Monsalve et al., 1990; Marcais et al., 2005; Priore et al., 2005;
Beigneux et al., 2009; Johansen et al., 2011). Affected indi-
viduals are either homozygous or compound heterozygous for
loss-of-function mutations in these genes involved in the reg-
ulation of catabolism of TRLs. Affected patients show substan-
tially increased fasting concentrations of CMs, but usually do
not develop premature atherosclerosis, probably because of size
exclusion that limits the ability of CMs to traverse the vascular
endothelial barrier (Xiong et al., 1991; Brunzell and Fujimoto,
1995; Johansen et al., 2011). Lipoprotein lipase deficiency (LPLD)
can be biochemically diagnosed by measurement of enzymatic
activity of LPL in post-heparin plasma or in adipose tissue (Wil-
son et al., 1990; Hegele et al., 2013). At present, the gold stan-
dard for diagnosis of Familial Chylomicronemia relies on DNA
FIGURE 2 | Vacuolar protein sorting 10 protein domain
receptor/sortilin and trygliceride-rich lipoprotein metabolism. (A)
Structural organization of VPS10P domain receptors from yeast
(VPS10P) and mammals (sortilin, SORLA). The extracellular domains of
the receptors are either composed of one or two VPS10P domains and
may carry additional modules involved in protein-protein interaction. EGF,
epidermal growth factor, SORLA, sorting protein-related receptor with
complement-type repeats. (B) SORLA may promote lipolysis of
trygliceride-rich lipoproteins through interaction with apolipoprotein A-V
and lipoprotein lipase (right side). Alternatively, lipoproteins can bind to
SORLA through cofactor apoA-V (left side) and LPL bound to heparin
sulfate proteoglycans (HSPG) on the cell surface.
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sequencing for detection of pathogenic mutations in LPL and/or
other candidate genes (Johansen et al., 2011).
Emerging Role of Sortilins in Triglyceride
Rich Lipoprotein Assembly
A number of new proteins have been recently identified as
important players in TRLs assembly.
Sortilin-1 is one of five members of a domain receptor family
of the trans-Golgi network and early endosomes known as vacuo-
lar protein sorting 10 proteins (Vps10p) (Charcosset et al., 2008).
It shows a wide range of ligands and it has been demonstrated
to play a role in the clearance of apoB-containing lipoproteins
(Strong and Rader, 2012). Sortilin serves as both a chaperone and
degrader of apoB-containing lipoproteins in a concentration-
dependent manner. Sortilin has been recently shown to play
a role in liver VLDL secretion. Specifically, low levels of sor-
tilin may be required for efficient VLDL export; on the other
hand higher expression of sortilin promotes the degradation of
presecretory VLDL (Wilson et al., 1990).
Recently, it has been proposed that ApoA-V acts as cofactor
for LPL through the binding of the complex of sortilin and/or
other sortilins (as sorting protein-related receptor containing
LDLR class A repeats—SORLA/LR11) on the heparan sulfate
proteoglycans (HSPG) of endothelial cell surfaces (Figure 2;
Babirak et al., 1989; Pennacchio et al., 2001; Van der Vliet et al.,
2001; Mendoza-Barbera et al., 2013).
SORLA is a multifunctional receptor expressed in
macrophages and vascular smooth muscle cells (SMC) (Van
der Vliet et al., 2001). It may act as proatherogenic factor by
promoting intimal SMC migration and by regulating apoA-V
dependent activation of LPL thus modulating triglyceride plasma
levels (Mendoza-Barbera et al., 2013). The expression of SORLA
gene is also modulated by factors inducing ER stress which is
emerging as an important modulator of atherosclerosis and
TRLs secretion (Willnow et al., 2011; Klingenberg et al., 2013;
Mendoza-Barbera et al., 2013).
Moreover, recent data from genome-wide association stud-
ies (GWAS) have underlined the role of sortilin-1 (SORT1) as
lipid regulatory gene in atherosclerotic cardiovascular disease
(Teslovich et al., 2010; Strong et al., 2014). In this context an
altered trafficking pathways may represent a major risk factor
for dyslipidemia and atherosclerosis in the human population
(Strong et al., 2014).
Conclusions
Intestinal lipoprotein production is a complex and multi-step
process that involves several and regulated pathways, involving
several genes. Recent insights in the understanding of the intesti-
nal and extra-intestinal mechanism of TRLs and their link to
atherosclerosis may hopefully facilitate the development of tar-
geted therapeutic approaches to the management of inherited
disorders affecting the triglyceride-rich lipoproteins metabolism.
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